At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.
In Brief
A Phase 4 clinical trial evaluating aspirin and clopidogrel for Coronary Heart Disease and 2 related conditions. Completed, enrolled 1,001 participants across 1 site.
Detailed Summary
In the ASCET study, 1000 patients with documented coronary heart disease will be randomized to either continued treatment with aspirin 160 mg/d or change to clopidogrel 75mg/d. Clinical endpoints will be recorded for at least 2 years and related to the initial aspirin response, assessed by the PFA-100® method, to investigate whether aspirin non-responders have higher composite event rate than responders or whether Clopidogrel treatment in patients non-responsive to aspirin will reduce their risk of future clinical events. The clinical events are the composite of unstable angina, myocardial infarction, stroke or death.
Study Details
Timeline
Interventions
Aspirin 160 mg once daily for two years
clopidogrel 75 mg once daily for two years